Vepotolizumab/Urova usually requires several courses of treatment

When Polatuzumab/Polatuzumab is used to treat diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma), the standard recommended regimen is intravenous infusion once every 21 days, with a dose of 1.8 mg/kg each time, usually for a total of 6 courses of treatment. In clinical practice, the setting of this dosing cycle is based on the metabolic dynamics and toxicity management balance of the drug. Studies have shown that 6 cycles can reduce the risk of cumulative neurotoxicity while maintaining efficacy.

Each course of treatment is often combined with other drugs, such as rituximab and bendamustine, to enhance anti-tumor activity. The initial phase of the first cycle requires close monitoring in the hospital to prevent infusion reactions or allergic reactions. If the patient develops significant neutropenia, fatigue or neurological symptoms during treatment, the doctor may adjust the dosing interval or reduce the dosage. If some patients have achieved complete remission after the mid-term course of treatment, the doctor can decide whether to continue to complete the full 6 cycles based on individual circumstances.

It needs to be emphasized that the treatment course setting of vepotuzumab has certain flexibility, and some clinical studies have also explored the possibility of being used in combination with theR-CHP regimen in patients with newly treated DLBCL. Early data suggests the combination can improve response rates and extend progression-free survival. On this basis, the future treatment direction may shift from "fixed 6 cycles" to "response-oriented treatment", that is, the treatment length is dynamically adjusted based on imaging evaluation and molecular residual disease detection.

Globally, the treatment course design of vepotuzumab reflects the concept of individualized treatment. Its core goal is to achieve the maximum therapeutic effect in the shortest time while controlling adverse reactions. For patients with relapsed or refractory lymphoma, 6 courses of treatment have become a standardized, scientific and widely verified treatment rhythm.

Reference materials:https://www.drugs.com/polivy.html